Total amount raised
$2.5 Billion
Latest funding date
10/01/2024
Location
Resilience has successfully navigated 9 funding rounds, securing investments from notable entities such as Oak Hill Advisors and the Administration for Strategic Preparedness and Response. The company recently announced significant financing milestones, including a $625 million Series D round and a $410 million partnership with the Department of Defense.
Resilience's mission to broaden access to complex medicines and protect biopharmaceutical supply chains is supported by its diverse investor base, which includes venture capital firms and government agencies. Keep reading to explore the intricacies of Resilience's fundraising journey and the investors backing this innovative platform.
What Is Resilience?
Resilience is a biomanufacturing company headquartered in La Jolla, California, with additional facilities in Blue Ash, Cincinnati, Philadelphia, and Toronto. The company operates in the biopharma, biotechnology, health care, life science, and pharmaceutical industries.
Founded to provide access to complex medicines and protect biopharmaceutical supply chains, Resilience employs between 501 and 1000 people. The company focuses on biologics, cell therapy, and gene therapy, emphasizing quality, speed, and sustainability in its operations.
How Much Funding Has Resilience Raised?
- Series A
- Amount Raised: USD 50,000,000
- Date: October 2020
- Lead Investors: Magnetic Ventures
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To establish the company's initial operations and infrastructure.
- Series B
- Amount Raised: USD 750,000,000
- Date: November 2020
- Lead Investors: 8VC, ARCH Venture Partners
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To expand biomanufacturing capabilities and secure supply chains.
- Series C
- Amount Raised: USD 600,000,000
- Date: August 2021
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To scale up production and enhance research and development.
- Series C
- Amount Raised: USD 80,000,000
- Date: November 2021
- Lead Investors: Not publicly disclosed
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To further expand manufacturing capabilities and support ongoing projects.
- Series D
- Amount Raised: USD 625,000,000
- Date: June 2022
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To accelerate growth and enhance biopharmaceutical production.
- Private Equity
- Date: January 2023
- Lead Investors: Mubadala
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To support strategic initiatives and long-term growth.
- Debt Financing
- Amount Raised: USD 410,000,000
- Date: March 2023
- Lead Investors: U.S. Department of Defense, U.S. International Development Finance Corp
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To establish an end-to-end biomanufacturing capacity.
- Grant
- Amount Raised: USD 17,500,000
- Date: October 2024
- Lead Investors: Administration for Strategic Preparedness and Response
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To expand domestic pharmaceutical manufacturing and enhance production of essential medicine components.
- Debt Financing
- Amount Raised: USD 825,000,000
- Date: October 2025
- Lead Investors: Oak Hill Advisors
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To further strengthen biopharmaceutical supply chains and support large-scale production.
Total Amount Raised: USD 3,367,500,000. Current Valuation: Not publicly disclosed.
Key Investors
- Oak Hill Advisors
- Details: Oak Hill Advisors is a leading alternative investment firm specializing in credit and distressed investments. They manage over $50 billion in capital across various strategies.
- Investment Focus Areas: Credit, distressed investments, private equity.
- Notable Investments: Resilience, American Airlines, Albertsons Companies.
- Administration for Strategic Preparedness and Response
- Details: The Administration for Strategic Preparedness and Response (ASPR) is a division of the U.S. Department of Health and Human Services focused on preparing for and responding to public health emergencies.
- Investment Focus Areas: Public health preparedness, biomanufacturing, supply chain security.
- Notable Investments: Resilience, various public health initiatives.
- U.S. Department of Defense
- Details: The U.S. Department of Defense (DoD) is responsible for coordinating and supervising all agencies and functions of the government related to national security and the armed forces.
- Investment Focus Areas: Defense, biomanufacturing, technology.
- Notable Investments: Resilience, various defense-related projects.
- U.S. International Development Finance Corp
- Details: The U.S. International Development Finance Corporation (DFC) is a government agency that provides financing for development projects in emerging markets.
- Investment Focus Areas: International development, finance, infrastructure.
- Notable Investments: Resilience, various international development projects.
- Mubadala
- Details: Mubadala is a sovereign wealth fund based in Abu Dhabi, managing a diverse portfolio of investments across multiple sectors globally.
- Investment Focus Areas: Technology, healthcare, energy.
- Notable Investments: Resilience, GlobalFoundries, Cepsa.
What's Next for Resilience?
Resilience is poised to capitalize on significant opportunities in the biomanufacturing sector, particularly through the expansion of domestic pharmaceutical manufacturing. With nearly $17.5 million in new funding, the company aims to enhance the production of essential medicine components, leveraging advanced biocatalysis technology in collaboration with Aralez Bio.
Future fundraising prospects look promising, with potential for additional public-private partnerships and government support to further bolster their manufacturing capabilities. However, Resilience may face challenges such as navigating regulatory approvals and maintaining consistent production quality. Despite these hurdles, the company is well-positioned to strengthen the U.S. pharmaceutical supply chain and ensure the availability of life-saving medications.
Use Clay to Get Funding Data
Sales professionals, leverage Clay’s platform to access comprehensive fundraising data on companies like Resilience and gather other critical business insights. Sign up for free to start transforming your sales strategy today.
